Everybody Loves Languages Reports Financial Results for the First Quarter Ended March 31, 2025
TORONTO — Everybody Loves Languages Corp. (' ELL ') (TSX-V: ELL; OTC: LMDCF; FSE: LIMA), www.everybodyloveslanguages.com, an edtech language learning edutainment and content development company, announces its financial results for the first quarter ended March 31, 2025. All figures are reported in Canadian Dollars and are in accordance with International Financial Reporting Standards unless otherwise noted.
Article content
Article content
Q1 2025 Financial Highlights
Article content
First Quarter Ended March 31 st
2025
2024
Revenue
$
362,953
$
149,977
Operating and development expenses
521,276
492,225
Loss before amortization, share-based payments, depreciation, finance charges and taxes
(158,323)
(436,754)
Amortization, share – based payments, and depreciation
10,163
14,408
Finance charges, taxes and foreign exchange
2,948
(56,195)
Net loss
(171,434)
(300,461)
Loss for the period attributable to:
Non-controlling interest
(7,010)
(6,981)
Shareholders of Everybody Loves Languages Corp.
(164,424)
(293,480)
Total comprehensive income
(170,506)
(312,327)
Total comprehensive loss for the period attributable to:
Non-controlling interest
(7,010)
(6,981)
Shareholders of Everybody Loves Languages Corp.
(163,496)
(305,346)
Earnings per share (basic)
$
(0.00)
$
(0.01)
Earnings per share (fully diluted)
$
(0.00)
$
(0.01)
Article content
Revenue for the first quarter ended March 31, 2025 totalled $362,953 as compared to $149,977 in Q1 2024.
Operating and development expenses for the quarter ended March 31, 2025, totalled $521,276 compared to $492,225 in Q1 2024.
Net loss for the quarter ended March 31, 2025, totalled $(171,434) or $(0.00) loss per share (basic) based on 35.6 million shares or $(0.00) loss per share (diluted) based on $36.1 million shares as compared to a net loss of $(300,461) for 2024 or $(0.01) loss per share (basic and fully diluted).
Loss before amortization, share-based payments, depreciation, finance charges and taxes was $(158,323) compared to $(436,754) in 2024.
Article content
'Everybody Loves Languages has introduced several important new features, most notably an AI-based tutor named AVI. We remain committed to enhancing our platform and are optimistic about a positive response from the market,' said Gali Bar-Ziv, President & CEO of Everybody Loves Languages.
Article content
The interim condensed financial statements for the quarter ended March 31, 2025, and Management Discussion & Analysis are available at www.sedarplus.ca
Article content
About Everybody Loves Languages Corp. (TSX-V: ELL; OTC: LMDCF; FSE: LIMA):
Article content
Everybody Loves Languages Corp. is an edtech language-learning and content development company empowering language educators to easily transition from traditional teaching methods to digital learning by integrating education, edutainment, and technology.
Article content
The company provides online and print-based solutions through two distinct business units: Everybody Loves Languages Inc. and Lingo Learning Inc. Everybody Loves Languages is a state-of-the-art technology platform that delivers personalized learning experiences in classrooms and online. Its programs provide innovative SaaS-based eLearning solutions, including online and offline content, a learning management system, assessments, real-time reports, speech recognition technology, and white-label tools. At the same time, Lingo Learning is the content development arm and co-publishes print-based English language learning materials in China.
Article content
Everybody Loves Languages has established successful relationships with key government and industry organizations internationally, with a presence in LATAM and China, and continues to expand its product offerings and extend its market reach.
Article content
Portions of this press release may include 'forward-looking statements' within the meaning of securities laws. These statements involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. These statements are based on management's current expectations and involve certain risks and uncertainties. Actual results may vary materially from management's expectations and projections and thus readers should not place undue reliance on forward-looking statements. Everybody Loves Languages has tried to identify these forward-looking statements by using words such as 'may,' 'should,' 'expect,' 'hope,' 'anticipate,' 'believe,' 'intend,' 'plan,' 'estimate' and similar expressions. Everybody Loves Languages' expectations depend upon general economic conditions, the continued and growth in demand for its products, retention of its key management and operating personnel, its need for and availability of additional capital and other uncontrollable or unknown factors. No assurance can be given that the actualresults will follow the forward-looking statements. Except as otherwise required by securities laws, Everybody Loves Languages undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, changed circumstances or any other reason. Certain factors that can affect the Company's ability to achieve projected results are described in the Company's filings with the Canadian securities regulators available on www.sedar.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
25 minutes ago
- National Post
WELL Health to Announce Second Quarter 2025 Financial Results on August 14, 2025
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2025 financial results for the period ended June 30, 2025, before the market opens on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). The call will be hosted by Hamed Shahbazi, Chairman and Chief Executive Officer and Eva Fong, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call. Article content Conference Call Participant Details Article content Date: Thursday, August 14, 2025 Article content Time: 1:00 PM ET / 10:00 AM PT Article content International Toll: 289-514-5100 Article content North American Toll Free: 1-800-717-1738 Article content To attend the webcast, register now or visit for details. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Corp. Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content
National Post
25 minutes ago
- National Post
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
Article content Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa ® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research Article content BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa ® technology. Article content These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa ® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers. Article content Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa ® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. Article content 'The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's,' said Masoud Toloue, PhD, CEO of Quanterix. 'Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we're advancing the future of precision diagnostics across neurology, oncology, and immunology.' Article content The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia. Article content To learn more about the new assays or Quanterix's expanded capabilities, visit or stop by the Quanterix booth at AAIC 2025. Article content About Quanterix Article content Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at Article content Article content Article content Article content Contacts Article content Media Contact: Marissa Klaassen (781) 913.8036 media@ Article content
Globe and Mail
25 minutes ago
- Globe and Mail
Leveraged ETFs take off in Canada, but hold on tight
Retail investors are increasingly turning to Canadian leveraged exchange-traded funds to weather – and even benefit from – the market volatility of on-again, off-again U.S. tariffs and threats. Leveraged ETFs have become the fastest-growing ETF category in the country as investors appear to be hungry for big returns and willing to accept the corresponding higher risks. In June, Canadian leveraged and inverse ETFs received $432-million in inflows, the highest percentage growth among all ETF asset classes in the country, according to a report by National Bank Financial. Leveraged ETFs use the power and complexity of derivatives, including total return swaps, futures and options to amplify performance. The funds can magnify gains or losses by two or three times compared with actual market returns. Inverse ETFs bet that a particular market or asset will fall. These specialized funds are inherently tactical and they are intended to be owned for only a few hours or days, at maximum, to take advantage of short-lived market conditions such as interest-rate announcements, economic data, or bellwether earnings reports, says Steve Hawkins, CEO of LongPoint ETFs. Heightened market volatility is one of the key drivers behind the popularity of leveraged funds, but they are best suited to moderate – not extreme – unpredictability, says Raghav Mehta, vice-president and ETF strategist with Global X Investments Canada Inc., which offers more than 32 leveraged ETFs through its BetaPro series. 'When the markets are clearly trending up, or clearly trending down smoothly, that's when the [leveraged] ETFs compound favourably over a couple of days,' Mr. Mehta says. 'We don't want to be owning these products when markets are super choppy and super volatile.' Owners of leveraged ETFs do not buy and hold, he adds. 'I like to call them 'traders' more than 'investors.' They are like speculators.' Toronto-based LongPoint and BetaPro lead the leveraged ETF category in Canada and they are beefing up their exposures in hopes of satisfying Canadian investors who previously sought out U.S. leveraged funds because of limited selection at home. According to LongPoint, there are 196 leveraged and inverse-leveraged exchange-traded products listed in the United States that track equity and fixed income indices, including 75 triple-leveraged (or higher) index funds. By contrast, Canada has a small fraction of that number, though it is growing. 'The big thing we are trying to do is repatriate Canadian investors to using Canadian ETFs versus going south of the border to use U.S. ETFs,' Mr. Hawkins says. Home-grown leveraged ETFs sidestep the tax, currency and administrative headaches for Canadian investors who used to seek out U.S. counterparts. Interest in higher-risk products is increasing. An Angus Reid Forum survey conducted for BetaPro late last year found that 27 per cent of more than 1,000 respondents said they would consider taking more investment risks, with 12 per cent interested in leveraged ETFs. The younger the investor, the higher the appetite for risk. 'We are now seeing a lot of people using these products and that is why issuers like us and others in the marketplace want to respond to this demand by launching more of these products,' Mr. Mehta says. These vehicles are predominately utilized by active investors who are looking for sophisticated investment strategies with reduced risk, Mr. Hawkins says. He described them as a 'one-ticket solution without having margin accounts, without having to deal with futures, without having to do all the inner workings to have your own leveraged exposure.' The investor's potential loss 'is limited to your initially invested principal,' Mr. Hawkins adds. 'You can't lose more, whereas with a future you can potentially lose more than what margin you put up.' That built-in sophistication and the daily adjustments come with sharply higher fees. Most leveraged ETFs charge 1.55 per cent of net asset value, compared with management-expense ratios for typical ETFs starting at 0.03 per cent and rising to 1 per cent for actively managed funds. But Mr. Hawkins points out that the heftier fee for leveraged funds works out to pennies when the products are held short term as intended, potentially worth the price for what would otherwise be a complex investment for a do-it-yourselfer.
